Alimentació

[p.4] Crisi? quina crisi?[p.8] El menjar com a mestre[p.17] Aprendre a desaprendre[p.21] Jo vull ser pagès[p.24] Per un canvi radical[p.32] Fam i obesitat, relacions i contradiccions[p.13] Alimentació i medicina[p.14] Educació del gust[p.20] Aprendre a l'hort?[p.27] "Quan mengis la fruita recorda't de qui la cultiva"[p.28] Universitats contra la fam[p.35] Diversitat alimentària a l'escola[p.36] Alimentació a escala humana[p.38] La dècada de l'educació per al desenvolupament sosteniblePeer Reviewe

Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice

BACKGROUND: Patients with transitional cell carcinoma of the urothelial tract (TCCU) who fail initial platinum-based chemotherapy for advanced disease represent a challenge in daily clinical practice. Vinflunine is approved by the European Medicine Agency (EMA) but, up to now, limited experience has been reported outside clinical trials. METHODS: We assessed the efficacy and safety of vinflunine in an unselected group of 102 consecutive patients with metastatic TCCU. RESULTS: The median age was 67 years (range 45–83). Among the most common comorbidities that patients presented at baseline were hypertension (50.5%) and diabetes (20.7%). Distant metastases were present in retroperitoneal nodes (58%), lung (29.3%), and bone (20.2%). The ECOG 0, 1 and 2 performance status at the start of vinflunine were 31.3%, 60.6% and 8.1%, respectively. The most commonly reported adverse events of any grade were constipation 70.6% (5.9% grade 3–4), vomiting 49.1% (2% grade 3–4), neutropenia 48.1% (12.8% grade 3–4) and abdominal pain 34.3% (4.9% grade 3–4). A median of 4 cycles of vinflunine was administered per patient (range 1–18). Median progression free and overall survival for all patients (N = 102) were 3.9 months (2.3-5.5) and 10 months (7.3-12.8), respectively. Time to tumor progression was 4.3 months (2.6-5.9). Two patients (2%) achieved CR, 23 (22.5%) patients had PR, and 42 (41.2%) presented SD as best response. The clinical benefit rate with vinflunine was 65.7%. CONCLUSIONS: Our results show that the behavior of vinflunine in routine clinical practice resembles that of the pivotal phase III randomized study

Optimization of Taxane Binding to Microtubules: Binding Affinity Dissection and Incremental Construction of a High-Affinity Analog of Paclitaxel

SummaryThe microtubule binding affinities of a series of synthetic taxanes have been measured with the aims of dissecting individual group contributions and obtaining a rationale for the design of novel compounds with the ability to overcome drug resistance. As previously observed for epothilones, the positive and negative contributions of the different substituents to the binding free energies are cumulative. By combining the most favorable substitutions we increased the binding affinity of paclitaxel 500-fold. Insight into the structural basis for this improvement was gained with molecular modeling and NMR data obtained for microtubule-bound docetaxel. Taxanes with affinities for microtubules well above their affinities for P-glycoprotein are shown not to be affected by multidrug resistance. This finding strongly indicates that optimization of the ligand-target interaction is a good strategy to overcome multidrug resistance mediated by efflux pumps

Alimentació

[p.4] Crisi? quina crisi?[p.8] El menjar com a mestre[p.17] Aprendre a desaprendre[p.21] Jo vull ser pagès[p.24] Per un canvi radical[p.32] Fam i obesitat, relacions i contradiccions[p.13] Alimentació i medicina[p.14] Educació del gust[p.20] Aprendre a l'hort?[p.27] "Quan mengis la fruita recorda't de qui la cultiva"[p.28] Universitats contra la fam[p.35] Diversitat alimentària a l'escola[p.36] Alimentació a escala humana[p.38] La dècada de l'educació per al desenvolupament sosteniblePeer Reviewe